The Zoono Group Ltd (ASX: ZNO) share price has been a very poor performer on Wednesday.
In afternoon trade the antimicrobial solutions provider’s shares are down a sizeable 9% to $1.68.
This latest decline means that the Zoono share price is now down by almost 50% since peaking at $3.29 in July.
Why is the Zoono share price sinking lower?
Investors have been selling Zoono’s shares following the release of its first quarter update this morning.
While that update reveals very strong sales growth in comparison to a year earlier, it also shows a sizeable slowdown in comparison to the last quarter.
Zoono, which sells antimicrobial hand sanitisers and sprays, reported first quarter sales of NZ$15 million. This is down 28.2% from the NZ$20.9 million it achieved in the fourth quarter of FY 2020.
If this level of sales can be maintained, it will deliver annual sales of NZ$60 million.
Judging by its share price performance today, investors may believe this isn’t enough to justify a A$300 million valuation, let alone the A$600 million market capitalisation it had in July.
What else did Zoono report?
Zoono reported positive operational cash flow for the quarter of NZ$2.8 million, down from NZ$5.3 million for the June 2020 quarter.
However, this couldn’t stop its cash at bank decreasing from NZ$10.3 million to NZ$7.5 million. Though, management notes this was driven largely by tax and dividend payments of NZ$7.5 million. Without these payments its cash balance would have been NZ$15 million.
At the end of the period the company had inventories of NZ$14.2 million available to meet current demand. Management advised that stock is held at strategic global locations to enable timely deliveries.
Should you invest?
I think investors would be better off keeping Zoono on their watchlist for now.
While I believe COVID-19 will lead to increased use of hand sanitiser over the long term, it is a highly competitive market.
In light of this, it is difficult to gauge just what level of sales Zoono will be able to maintain in the coming quarters.
As a result, I would suggest investors wait for things to settle down before trying to value the company.
In the meantime, I would sooner buy a healthcare share such as CSL Limited (ASX: CSL) ahead of Zoono.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.